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Sllmmary 
Presentation of antigenic peptides by major histocompatibility complex (MHC) class I molecules 
requires MHC-encoded molecules of the adenosine triphosphate binding cassette (ABC) family. 
Defects in these proteins represent a potential risk, since they are essential links in the machinery 
of T cell-mediated surveillance which continuously scrutinizes peptide samples of cellular proteins. 
Nevertheless,  transfection of the mouse lymphoma mutant RMA-S with the rat ABC gene mtp2  ~ 
(homologue to mouse HAM2 and human RINGI1),  commonly termed TAP-2 genes, led to 
a marked increase in tumor outgrowth potential in vivo. This occurred despite restored antigen 
presentation and sensitivity to cytotoxic T lymphocytes, and was found to be due to escape from 
natural killer (NK) cell-mediated rejection. It has previously been proposed that adequate expression 
of sdf-MHC dass I is one important mechanism to avoid dimination by NK cells. Our data 
argue that a defect in the machinery responsible for processing and loading of peptides into MHC 
class I molecules is sufficient to render cells sensitive to elimination by NK cells. The latter thus 
appear to function as a surveillance of the peptide surveillance machinery. 
M 
HC class I molecules present short antigenic peptides 
to  CD8 +  cytotoxic  T  cells  (1-3).  The  peptides 
presented are derived from cytosolic proteins, usually trans- 
lated endogenously (2). There are at least two genes in the 
MHC that code for products involved in peptide supply to 
MHC class I molecules, termed TAP-I  and TAP-2. These 
products are homologous to the transport proteins in the ATP 
binding cassette (ABC) family, and are thought to mediate 
transport from the cytoplasm to the endoplasmic reticulum, 
either of peptides or a cofactor essential for peptide loading 
into MHC class I molecules (4-13). The mouse lymphoma 
mutant RMA-S has a profound (14-16), but not total (17-19), 
peptide presentation defect in the MHC class I presentation 
pathway, which is due to a premature stop in the message 
of the mouse TAP-2 gene HAM2 (19a). The phenotype was 
restored to  normal by transfection of TAP-2 genes from 
different species,  first the ratp2  ~ rat gene (9)  and then the 
HAM2 mouse gene (12) and the RINGII  human gene (A. 
Townsend, personal communication); the mtp2" transfectant 
(RMA-S.mtp2')  was able to process and present influenza 
virus epitopes to CD8 + T cells (9). This transfectant system 
has now made it possible to investigate directly the role of 
TAP genes for in vivo phenomena such as tumorigenicity 
and transplant rejection. The aim of the present study was 
to investigate the effects on in vivo immunobiology of RMA-S 
after restoration of its antigen presentation defect by the rat 
TAP-2 gene. 
Materials and Methods 
Animals.  C57BL/6  mice were bred  and maintained  at  the 
Department of Tumor Biology, Karolinska Institutet.  Athymic 
nu/nu C57BL/6 mice were purchased from Bomholtgaarden, Den- 
mark. All mice were 4-8 wk old at the start of the experiments. 
Tumor Cell Lines.  RMA (derived from RBL-5 after mutageni- 
zation, nonselected [20, 21]), RMA-S (derived from RBL-5 after 
mutagenization and selection with anti-H-2  b antiserum plus com- 
plement for loss of MHC class I expression [20, 21]), and RMA- 
S.mpt2" (RMA-S  transfected with  mtp2  ~ cDNA;  a  neomycin- 
resistant expression  vector driven by the/3-actin promoter [9]) were 
grown in RPMI  1640 supplemented with penicillin and strep- 
tomycin plus 5% FCS and kept in 50-ml culture flasks at 370C, 
5% COz. The tissue-cultured medium of RMA-S.mtp2" was sup- 
plemented with G418 1 mg/ml to maintain the plasmid. 
In Vivo Rejection Assay.  Untreated and NKI.1 antibody-treated 
(0.2 ml NKI.1 ascitic fluid intraperitoneaUy,  days - 1 and + 5) syn- 
geneic C57BL/6 mice were used. Tumor cells were inoculated sub- 
cutaneously either in separate flanks or in separate animals, and 
outgrowth was monitored by palpations twice weekly. Tumors ap- 
peared at the site of inoculation,  grew progressively, and subse- 
quently killed the mice. In vitro tumor ceU lines, phenotypicaUy 
indistinguishable from the injected tumor cell llne, could regularly 
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tally, metastases were not observed. However, if single cell suspen- 
sions were prepared from different organs,  e.g., spleen,  in vitro 
tumor cell lines could occasionally be established, which were pheno- 
typically indistinguishable from the injected tumor cell line (data 
not shown). After initial experiments, the mice were killed when 
the mean tumor diameter reached 15 mm and no signs of regres- 
sion were seen. The tumors were examined macroscopically after 
killing the animals.  Mice without tumor growth were observed 
for at least  8 wk after inoculation. 
Short-Terra In  Vivo Rejection Assay with I2sI-UdR-labelecl Cells. 
Untreated and NKI.1 antibody-treated (0.2 ml NKI.1 ascitic fluid 
intraperitoneally 24 h before the test) syngeneic C57BL/6 mice 
were used.  20  x  10  ~ tumor cells (ILMA,  ILMA-S, and ILMA- 
S.mtp2', respectively)  were incubated in 20 ml P~MI plus 5% 
FCS plus 10 #Ci 12sI-UdR at 37~  for 5 h, washed three times, 
and diluted to a final concentration of 5  x  106 cells/ml. 200 #1 
(106 cells) of the cell preparations was injected intravenously.  The 
mice were killed after 8 h and the remaining radioactivity was mea- 
sured in the lungs, the liver, the spleen, and the kidneys, in a gamma 
counter (Pharmada-LKB Biotechnology, Stockholm, Sweden). The 
arithmetic means and SD in each group (five mice/group) from 
one representative experiment are given. 
In Vitro Cytotoxic Assay with Antibody plus Complement-depleted 
Elector Cell Populations.  NK cell activity of syngeneic C57BL/6 
mice was boosted by administrating 0.2 ml of a 10 mg/ml prepara- 
tion of tilorone analogue K10.874 DA (Sigma Chemical Co., St. 
Louis, MO) per os to each animal on day -1. Tilorone augments 
NK cell activity by induction of IFN in the host (22). Single cell 
suspensions  of spleens from the tilorone-boosted mice were pre- 
pared in tissue culture medium. Aliquots of 20  x  106 cells were 
incubated with 1.5 ml of mAb for 45 min, washed twice in PBS, 
incubated in 1.5 ml of rabbit complement for 60 min at 37~ 
5% COs, washed twice in PBS, and finally diluted in tissue cul- 
ture medium. Reagents used were rabbit complement (Pd-Freez, 
Brown Deer, WI) diluted 1:8, anti-CD4 (ILM-4-4; PharMingen, 
Scan Bintech, Falkenberg,  Sweden) diluted 1:100, anti-CD8 (YTS 
169.4; Sera-lab, Kemila, Stockhohn, Sweden) diluted 1:500, and 
anti-asialo-GM1 (Wako Chemicals, Dfisseldorf,  Germany) dihited 
1:100. Dilutions were made in tissue culture medium, and the prepa- 
rations were used as effectors, tLMA, RMA-S, and RMA-S.mtp2 a 
were used as targets. A  standard 4-h SlCr-release assay was per- 
formed as previously described (23) with the effector/target ratios 
100:1, 33:1,  and 11:1. 
Results  and Discussion 
RMA-S.mtp2' had a somewhat lower growth rate in vitro 
as compared with tLMA-S (data not shown). Despite this, 
the transfectant had acquired a malignant phenotype. In con- 
trast with the mutant,  the mtp2  a transfectant grew out in 
the majority (70%) of animals after subcutaneous inocula- 
tion of 103 cells (Fig.  1 A).  The mutant failed to grow in 
more than 20% of the animals even after a 100-fold increase 
of the inocuhm  to 105 cells, a dose that resulted in 100% 
tumor outgrowth of transfectant cells (Fig. 1 B). The differ- 
ence in tumorigenicity between mutant and transfectant cells 
persisted in T cell-deficient nude mice (data not shown), but 
disappeared in animals  treated with anti-NKl.1  antibodies 
(Table 1).  The tumorigenicity of the transfectant was due 
to its capacity to escape from rapid elimination by NK cells. 
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In vivo outgrowth of RMA (O), ILMA-S (O), and tLMA- 
S.mtp2" (A) lymphoma cells in syngeneic  C57BL/6 mice. (A) 10~ tumor 
cells injected  subcutaneously  and outgrowth monitored  by palpations twice 
weekly; (B) 10  s tumor cells injected subcutaneously  and outgrowth moni- 
tored by palpations twice weekly. Means of three separate experiments, 
with a total of 12-15 mice in each group are Oven. 
Radiolabeled, intravenously inoculated transfectant ceils sur- 
vived well in the lungs (Fig.  2) and liver (data not shown) 
in normal as well as in NKl.l-treated animals, whereas the 
mutant cells without mtp2  ~ survived only in the latter. The 
ratp2  ~ transfection also  rendered R.MA-S  resistant  to  NK 
cells in vitro (Fig.  3, A  and B). 
To our knowledge, this change in tumor cell rejectability 
is the first direct demonstration that a MHC-encoded trans- 
porter gent can have a decisive influence on disease progres- 
sion in vivo. The result may seem surprising, since one might 
Table  1.  In  Vivo Outgrowth of RMA-S and RMA-S, mtp2, 
Lymphoma Cells in  Untreated and NKI.I  Pretreated Syngeneic 
C57BL/6 Mice 
Host NKI.1 
Host untreated  pretreated 
tLMA-S,  tLMA-S. 
Cells  injected  ILMA-S  mtp2,  RMA-S  mtp2, 
Separate  flanks  0/8  7/8  8/8  8/8 
Separate  animals  3/13  15/15  14/15  15/15 
In vivo outgrowth of 10  s RMA-S and RMA-S.mtp2, lyraphoma cells 
in untreated and NK. 1 antibody-treated syngeneic C57BL/6 mice after 
subcutaneous inoculations. 
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Figure  2.  Short-term in  vivo survival of tzsI-UdR-labded RMA, 
RMA-S, and RMA-S.mtp2* lymphoma cells in untreated and NKI.1 
antibody-treated syngeneic  C57BL/6 mice. 106 tumor cells were injected 
intravenously and the rernaining radioactivity  in the lungs was determined 
after 8 h. The arithmetic means and SD in each group from one represen- 
tative experiment are given. 
expect a restored antigen presentation to benefit the host rather 
than the tumor. However, the present system involves NK 
calls as important antitumor effector cells, and the outcome 
may be different when T ceils dominate the scene. The low 
malignancy and the  NK  sensitivity of RMA-S  has  been 
reported previously (20, 21, 24, 25), but it was not known 
whether any of these properties was directly related to the 
defect in MHC-encoded transporter genes. From other ex- 
perimental systems, it is dear that correction for a H chain 
gene or ~z-microglobulin (~zm)  gene defect  can  also be 
sufficient to restore a phenotype permitting escape from NK 
cells in vivo (26-28). In vitro studies of NK sensitivity have 
shown the same pattern (29-33). The component in the MHC 
class I molecule that is critical for protection against NK rec- 
ognition remains to be identified, even  if data from site-directed 
mutagenesis experiments strongly imply a role for peptides 
and/or the peptide binding groove of the H chain (31, 34). 
The present results are in line with this idea. 
There is a mutual stabilizing effect of peptide and 152m 
binding to the H  chain. Conversely,  dissociation from the 
H  chain of either peptide or 32m rapidly leads to irrevers- 
ible loss of the tertiary structure and the antigen binding deft 
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Figure 3.  Sensitivity of RMA,  RMA-S, and RMA-S.mtp2= to syn- 
geneic C57BL/6 and aiiogeneic BALB/c  NK effector  cells. (A) Syngeneic 
C57BL/6 (O) and allogeneic BALB/c (@) NK effector cells were tested 
at effector/target ratios 300, 100, and 33:1. (B) Syngeneic  C57BL/6 spleen 
effector cells were pretreated either with C' (@), anti-CD4+  C' (A), anti- 
CDS+ C' (A), anti-asialo-GMl+ C' (D), or left untreated (O), and tested 
at effector/target ratios 300, 100, and 33:1. 
(14, 35-39). Thus, the molecular machinery fixed by evolu- 
tion for the MHC class I pathway provided a peptide-carrier 
system under considerable dissociative stress. This reduces the 
risk of binding novel peptides after the molecule has reached 
the cell surface, which is essential to avoid "innocent bystander 
killing" of normal cells binding external peptides. Another 
consequence is that any defect leading to impaired antigen 
presentation, be it in the H  chain (26,  27),  B2m (28)  or 
supply of peptides, wiU lead to reduced cell surface expres- 
sion of H  chain and a NK-sensitive phenotype. In light of 
our finding that a defect in one gene product in the processing 
machinery is sufficient to make a ceU target for rapid dimi- 
nution, it appears that NK ceils fulfill one important proof- 
readingAcavenger function necessary for full ef~dency of T 
cell surveillance. 
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